 SAB Biotherapeutics Inc NASDAQ: SABS has announced data from a Phase 2a challenge study of SAB-176, its investigational therapy for treating seasonal influenza. SAB-176 is a quadrivalent fully human polyclonal antibody therapeutic candidate designed to treat moderate to severe Type A and B seasonal influenza viruses. 